Clinical Trials Detalhe
Postmarket Evaluation of the Phased Radio Frequency Ablation System (GOLD AF Registry)
Visão Geral
Gender
ALL
Idade
N/A
Fase
N/D
Tipo de Estudo
OBSERVATIONAL
Localização
Centro Hospitalar Lisboa Notre - Hospital de Santa Maria E.P.E. (Lisbon, Portugal)
Clinicaltrial.gov
https://classic.clinicaltrials.gov/ct2/show/NCT02433613Sumário
Prospective, multi-center, single-arm, non-interventional and open-label registry. The purpose of the registry is to document use of Phased Radio Frequency Ablation (RFA) (hereafter "Phased RFA") System in a real world patient population with atrial fibrillation (AF) and evaluate its performance. Gold AF will enroll a minimum of 1,000 patients who undergo Phased RFA in approximately 38 sites in Western, Central Europe, Israel and South Korea.
Condições
Atrial Fibrillation
Elegibilidade
Inclusion criteria: * Patient with AF who is scheduled for Phased RFA procedure * Patient signed patient informed consent or patient data release form * Age ≥18 years old To avoid enrollment bias in this cohort of patient and reflect "real world" clinical practice for Phased RFA no exclusion criteria will be defined.